Ernexa Therapeutics Advances ERNA-101 Cell Therapy for Ovarian Cancer Following FDA Alignment and Promising Preclinical Data
核心洞察
Ernexa Therapeutics (搜索) successfully completed a Pre-IND meeting with the FDA, receiving regulatory alignment for its ERNA-101 cell therapy development approach for ovarian cancer treatment.
Preclinical data presented at ASH demonstrated that ERNA-101's engineered iMSCs achieved 20-fold higher cytokine production levels compared to engineered T-cell approaches, converting "cold" tumors to "hot" inflammatory microenvironments.
The company has initiated tech transfer for clinical manufacturing and remains on track to begin first-in-human trials in the second half of 2026.
Ernexa Therapeutics (搜索) has achieved significant regulatory and scientific milestones for its lead cell therapy candidate ERNA-101, positioning the company to advance toward first-in-human trials for ovarian cancer treatment in the second half of 2026. The company recently completed a successful Pre-IND meeting with the FDA and presented compelling preclinical data at the American Society of Hematology Annual Meeting.
FDA Provides Regulatory Pathway
The FDA's feedback during the Pre-IND meeting validated Ernexa's development strategy and established a clear pathway for IND submission. "We are very pleased with the outcome of our engagement with the FDA," said Sanjeev Luther, President and CEO of Ernexa Therapeutics (搜索). "The Agency's feedback validates our development strategy and gives us the green light to move forward with urgency."
Following the regulatory alignment, Ernexa has accelerated operational activities, with tech transfer already underway to prepare for clinical manufacturing. This represents one of the most significant milestones in preparing for clinical-grade material production and trial readiness.
Breakthrough Preclinical Results Transform Tumor Microenvironments
Preclinical data presented at ASH demonstrated ERNA-101's ability to reprogram immunosuppressive tumor microenvironments into immune-active, pro-inflammatory states. The study, conducted in collaboration with investigators at MD Anderson Cancer Center, showed that iMSCs engineered to secrete interleukin-7 (IL-7) and interleukin-15 (IL-15 (搜索)) achieved supraphysiologic cytokine production levels approximately 20-fold higher than levels previously reported in engineered T-cell approaches.
"These data highlight the potential of iPSC-derived MSCs and their ability to be repurposed from their historical immunosuppressive roles into highly effective, immune-activating delivery vehicles," said Michael Andreeff, M.D., Ph.D., Professor of Medicine at The University of Texas MD Anderson Cancer Center and lead author on the study.
Significant Therapeutic Impact in Ovarian Cancer Model
In an immunocompetent ovarian cancer model, intraperitoneal administration of IL-7/IL-15 (搜索)-secreting iMSCs resulted in significant immune cell infiltration into tumors, macrophage polarization toward a pro-inflammatory phenotype, and prolonged survival. The treatment successfully transitioned tumors from an immune-excluded ("cold") state to a highly inflamed ("hot") microenvironment, a key prerequisite for responsiveness to modern immunotherapies.
The high cytokine production levels corresponded to robust T-cell expansion and activation, sustained STAT5 (搜索) signaling, and upregulation of survival pathways critical to immune persistence.
Scalable Off-the-Shelf Platform Technology
ERNA-101 represents a best-in-class approach using synthetic, allogeneic iMSCs derived from induced pluripotent stem cells (iPSCs). This platform provides a scalable, off-the-shelf treatment solution without requiring patient-specific cell harvesting. The engineered iMSCs are designed to actively home in on tumors and deliver potent therapeutic cytokines directly to the disease site.
"These data represent an important validation of our platform and reinforce our belief that iPSC-derived MSCs can be engineered into powerful immune-modulating agents," Luther noted. "We believe our ability to manufacture clonal, gene-modified cells at scale gives us a meaningful competitive advantage as we advance toward clinical development."
Addressing Unmet Medical Need in Ovarian Cancer
Ernexa's initial clinical development focuses on ovarian cancer, a disease characterized by limited effective targeted therapies and high recurrence rates. The company's approach aims to overcome resistance in both solid tumors and hematologic malignancies through its platform's ability to deliver cytokines directly into tumors and reprogram the immune ecosystem.
The company is also developing ERNA-201 (搜索), a cell therapy product designed to target inflammation and treat autoimmune disease, demonstrating the platform's potential across multiple therapeutic areas.